clobetasol 17-propionate/salicylic acid/retinoic acid/urea (GN-037) / Gen Ilaç ve Saglik Ürünleri - LARVOL DELTA

A Multicenter Randomized Double-Blind Vehicle-Controlled Parallel Group Phase 2 Study Evaluating the Efficacy and Safety of GN-037 Cream in Patients with Mild-to-Moderate Plaque Psoriasis. (PubMed, Dermatol Ther (Heidelb)) - P2 | "GN-037 was more effective than V in achieving primary and all secondary endpoints throughout the study. Safety data did not reveal any new safety concerns with the combination cream product. Therefore, 4 weeks of GN-037 treatment demonstrated an excellent efficacy and safety profile in patients with MMPP."

Journal • P2 data • Dermatology • Immunology • Psoriasis

A Multicenter Randomized Double-blind Vehicle-controlled Parallel Group Phase 2 Study Evaluating the Safety and Efficacy of GN-037 Cream in patients with Mild to Moderate Plaque Psoriasis (EADV 2024) - P2 | "However, there is an unmet need to develop novel formulations containing lower concentrations of commonly prescribed highly potent corticosteroids such as clobetasol 17-propionate (CP) to provide a better benefit-risk ratio. GN-037 was more effective than V in achieving primary and secondary end points at week 4. Safety data did not reveal any new safety concerns with the combination cream product. Therefore, 4 weeks of GN-037 treatment demonstrated an excellent efficacy and safety profile in patients with MMPP."

Clinical • P2 data • Dermatology • Immunology • Psoriasis

GEN Announces Positive Phase 2 Clinical Trial Results for GN-037 Topical Cream in Patients With Mild to Moderate Plaque Psoriasis (ACCESSWIRE) - P2 | N=190 | NCT05706870 | Sponsor: GEN İlaç ve Sağlık Ürünleri A.Ş. | "The findings were presented at Amsterdam's European Academy of Dermatology and Venereology (EADV) 2024 Congress.....The GN-037 Phase 2 trial met the primary endpoint: treatment success,defined as the percentage of patients with at least a 2-grade improvement in Investigator's Global Assessment (IGA) score and achieving an IGA score of 0 or 1. 37.9% of patients treated with GN-037 achieved treatment success at week four compared to 9.1% in the placebo group (P=0.006). GN-037 demonstrated significant improvements in reducing erythema (57.6%, P=0.008), plaque elevation (72.7%, P=0.001), and scaling (80.3%, P=0.006) compared to placebo. 31.8% of patients in the GN-037 group achieved at least a 75% reduction in PASI, compared to 6.1% in the placebo group (P=0.009)."

P2 data • Psoriasis

New Topical Combination Formulas in Dermatology (INDERCOS 2024) - "In a clinical study including 60 patients with mild-moderate facial acne the efficacy and safety of Tazarotene 0.1% Plus Clindamycin 1% Gel Versus Adapalene 0.1% Plus Clindamycin 1% Gel was examined...In markets, Epiduo fort gel including 0.3% adapalene and 2.5% BPO is also available for mild-moderate acne vulgaris...Besides, Twyneo (a fixed dose comb...For the use of accompanying disorders with acne vulgaris such as acne and melasma the triple combination including Retinoic acid 0.025, Clindamycin 2%, Hydroquinone 4%; for acne and hirsutism double combination of Clindamycin 2% and Eflornithine 11.5%; for acne and seborrheic dermatitis Clotrimazole 1% and Erythromycin 2% are all available...Numerous products such as thermal waters and a variety of creams pharmaceutical compounding offers the advantage of combining with metronidazole or topical antiirritants (e.g., enoxolone, alpha bisabolol) and venotonic agents to prevent disease progression.For sensitive skin and..."

Acne Vulgaris • Alopecia • Dermatitis • Dermatology • Dermatopathology • Immunology • Infectious Disease • Obesity • Psoriasis • Rosacea • Seborrheic Dermatitis

Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis (clinicaltrials.gov) - P2 | N=190 | Completed | Sponsor: GEN İlaç ve Sağlık Ürünleri A.Ş. | Active, not recruiting ➔ Completed

Trial completion • Dermatology • Immunology • Psoriasis